183.05
5.70 (3.21%)
| Penutupan Terdahulu | 177.35 |
| Buka | 179.54 |
| Jumlah Dagangan | 596,052 |
| Purata Dagangan (3B) | 1,241,295 |
| Modal Pasaran | 26,864,148,480 |
| Harga / Pendapatan (P/E TTM) | 20.80 |
| Harga / Pendapatan (P/E Ke hadapan) | 12.38 |
| Harga / Jualan (P/S) | 2.74 |
| Harga / Buku (P/B) | 1.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2026 |
| Margin Keuntungan | 15.07% |
| Margin Operasi (TTM) | 28.05% |
| EPS Cair (TTM) | 10.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -38.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 39.00% |
| Nisbah Semasa (MRQ) | 1.44 |
| Aliran Tunai Operasi (OCF TTM) | 2.58 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.43 B |
| Pulangan Atas Aset (ROA TTM) | 5.43% |
| Pulangan Atas Ekuiti (ROE TTM) | 9.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Menaik | Bercampur |
| Drug Manufacturers - General (Global) | Menaik | Bercampur | |
| Stok | Biogen Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.25 |
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 0.19% |
| % Dimiliki oleh Institusi | 92.79% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 246.00 (Guggenheim, 34.39%) | Beli |
| Median | 215.00 (17.45%) | |
| Rendah | 177.00 (Piper Sandler, -3.31%) | Pegang |
| Purata | 210.00 (14.72%) | |
| Jumlah | 6 Beli, 7 Pegang | |
| Harga Purata @ Panggilan | 192.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 20 Feb 2026 | 185.00 (1.07%) | Pegang | 192.03 |
| Wedbush | 10 Feb 2026 | 187.00 (2.16%) | Pegang | 188.99 |
| 09 Feb 2026 | 187.00 (2.16%) | Pegang | 193.81 | |
| BMO Capital | 09 Feb 2026 | 196.00 (7.07%) | Pegang | 193.81 |
| Canaccord Genuity | 09 Feb 2026 | 230.00 (25.65%) | Beli | 193.81 |
| Citigroup | 09 Feb 2026 | 215.00 (17.45%) | Pegang | 193.81 |
| Guggenheim | 09 Feb 2026 | 246.00 (34.39%) | Beli | 193.81 |
| HC Wainwright & Co. | 09 Feb 2026 | 228.00 (24.56%) | Beli | 193.81 |
| Piper Sandler | 09 Feb 2026 | 177.00 (-3.31%) | Pegang | 193.81 |
| RBC Capital | 09 Feb 2026 | 233.00 (27.29%) | Beli | 193.81 |
| TD Cowen | 09 Feb 2026 | 215.00 (17.45%) | Beli | 193.81 |
| Truist Securities | 09 Feb 2026 | 193.00 (5.44%) | Pegang | 193.81 |
| Wells Fargo | 09 Feb 2026 | 200.00 (9.26%) | Pegang | 193.81 |
| Oppenheimer | 30 Jan 2026 | 225.00 (22.92%) | Beli | 179.89 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy |
| 04 Feb 2026 | Pengumuman | Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |